EAACI, Glasgow 2025 – A great success! Showcasing egg, milk and peanut food challenges and a cashew food challenge concept.

2025 has been a huge year for the growth and expansion of Reacta Healthcare and EAACI 2025 was a fantastic opportunity to showcase our multi-allergen product range of peanut, milk, and egg as well as introduce our innovation pipeline: cashew and products suitable from 6 months.

EAACI allows us to connect with clients and researchers from the allergy field. Over the weekend, various flash talks gave insight to how important oral food challenges are. Including future clinical practice using oral food challenges. Alexsandra Odoi discussed the use of algorithms from routinely collected data of allergy sufferers to determine the likelihood that future generations would be sufferers of food allergies and if the use of an oral food challenge would be beneficial. Mohamed Shamji demonstrated the future uses of AI in allergy diagnosis and treatment. This talk focused not only on diagnosis but on personalised immunotherapy where the use of oral food challenges can be delivered in personalised doses based on previous data collected for that participant.

Our R&D scientist Callum McKenry was part of the exhibition team, “Working on the booth really proved how forward thinking and unique Reacta is. It was a fantastic opportunity to find out about current and future clinical practice, what future products are needed, regional variation in food allergies such as sesame, shellfish, and even less common allergies such as rice. Attending EAACI gave me a unique insight into the needs of our clients, which are pharmaceutical companies running therapeutic clinical trials. Our clients are striving for solutions to improve the quality of life for those with food allergies.”

The global allergy community comes together each year at EAACI, it is an invaluable opportunity for Reacta Healthcare to understand the food allergy environment. We need to understand the challenges that both patients and clinicians face on a daily basis, and get ready for future innovations in diagnosis, treatment and prevention. Belinda Mortelli, Head of Commercial concluded, “EAACI allows us to meet our existing portfolio of international clients and ensure that other companies, involved with clinical trials, know that we are the market leader for pharmaceutical oral food challenge products. We are ready to meet their bespoke needs and encourage potential buyers to get in touch as early as possible in the development of their clinical study protocol to discuss requirements. Reacta have experience supplying clinical trials across the world since 2017, shipping products globally. We move forward with our preparation for the next conference exhibition: ACAAI, Orlando, 6-10 November.”